Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Dose-Escalation in Adult T‑cell Leukemia-Lymphoma and Peripheral T‑cell Lymphoma
jRCT2080221768Phase 1
- Sponsor
- Celgene Corporation
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL), sponsored by Celgene Corporation.
02
Drugs
lenalidomide
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT2080221768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221768.